Arrowhead Pharmaceuticals (ARWR) Short term Debt (2024 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 3 years of Short term Debt data on file, last reported at $40.0 million in Q1 2026.

• Quarterly Short term Debt fell 38.46% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 38.46% YoY) and the FY2025 annual result came in at $40.0 million, changed N/A from the prior year.
• Short term Debt steadied at $40.0 million in Q1 2026, from $40.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $65.0 million in Q1 2025 to a low of $1.6 million in Q4 2024.
• A 3-year average of $37.8 million and a median of $40.0 million in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2025 — Short term Debt surged 2361.54% — and 2026, when it slumped 38.46%.
• Tracing ARWR's Short term Debt over 3 years: stood at $1.6 million in 2024, then surged by 2361.54% to $40.0 million in 2025, then changed by 0.0% to $40.0 million in 2026.
• The last three Short term Debt figures came in at $40.0 million (Q1 2026), $40.0 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.